Skip to main content

Advertisement

SpringerLink
Log in

The role of exercise testing in the evaluation of the patient with hypertrophic cardiomyopathy

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disease of the sarcomeric contractile proteins that is characterized by left ventricular hypertrophy and myocyte disarray. The majority of patients are limited in terms of functional capacity and a minority die suddenly. The main aims of management are symptom alleviation and prevention of sudden cardiac death. In patients with HCM, cardiopulmonary exercise testing provides a more accurate index of functional capacity than New York Heart Association classification status and is useful in assessing symptoms following various therapeutic interventions. Cardiopulmonary exercise testing plays an important role in differentiating HCM from other conditions associated with left ventricular hypertrophy. Cardiopulmonary exercise testing is also valuable in identifying individuals at high risk of sudden cardiac death and is an integral part of the algorithm in risk stratification and delivery of prophylactic therapy. Over the past few years, cardiopulmonary exercise testing has provided insight into the determinants and mechanisms of exercise limitation. This understanding helps in targeting therapy and the development of new treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775–785.

    Article  PubMed  CAS  Google Scholar 

  2. Mogensen J, Klausen IC, Pedersen AK, et al.: Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103:R39-R43.

    PubMed  CAS  Google Scholar 

  3. Kimura A, Harada H, Park J-E, et al.: Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1996, 13:63–69.

    Article  Google Scholar 

  4. Thierfelder L, Watkins H, MacRae C, et al.: Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994, 77:701–712.

    Article  PubMed  Google Scholar 

  5. Watkins H, Conner D, Thierfelder L, et al.: Mutation in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:434–437.

    Article  PubMed  CAS  Google Scholar 

  6. Frank S, Braunwald E: Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 1968, 37:759–788.

    PubMed  CAS  Google Scholar 

  7. Maron BJ, Bonow RO, Canon ROIII, et al.: Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology and therapy. N Eng J Med 1987, 316:780–789, 844–852.

    Article  CAS  Google Scholar 

  8. Braunwald E, Morrow AG, Cornelli WP, et al.: Idiopathic hypertrophic subaortic stenosis: clinical, haemodynamic and angiographic manifestations. Am J Med 1960, 29:924–945.

    Article  Google Scholar 

  9. McKenna WJ, Elliott PM: Hypertrophic cardiomyopathy. In Comprehensive Cardiovascular Medicine. Edited by Topol EJ. Philadelphia: Lippincott-Raven; 1998:775–798.

    Google Scholar 

  10. McKenna WJ, Deanfield JE: Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984, 59:971–975.

    Article  PubMed  CAS  Google Scholar 

  11. Spirito P, Chiarella F, Carratino L, et al.: Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatients population. N Eng J Med 1989, 320:749–755.

    Article  CAS  Google Scholar 

  12. McKenna WJ, Franklin RCG, Nihoyannopoulos P, et al.: Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988, 11:147–153.

    Article  PubMed  CAS  Google Scholar 

  13. Wasserman K, Hansen JE, Sue D, Whipp B: Principles of exercise testing and interpretation.Philadelphia: Lea & Febiger; 1987.

    Google Scholar 

  14. Sadoul N, Prasad K, Elliott PM, et al.: Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96:2987–2991.

    PubMed  CAS  Google Scholar 

  15. Jones S, Elliott PM, Sharma S, et al.: Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998, 80:60–67. Severe abnormalities in maximal and submaximal cardiopulmonary exercise indices are seen in HCM patients. These abnormalities indicate that reduced stoke volume response, ventilation/perfusion mismatching or abnormal peripheral oxygen utilization are possible mechanisms involved in exercise limitation.

    PubMed  CAS  Google Scholar 

  16. Sharma S, Elliott PM, Whyte G, et al.: Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000, 86:162–168. Hypertrophic cardiomyopathy is associated with subnormal functional capacity in most cases. Abnormal blood pressure responses, chronotropic incompetence, and outflow tract obstruction were particularly related with exercise limitation.

    Article  PubMed  CAS  Google Scholar 

  17. Savage DD, Seides SF, Clark CE, et al.: Electrocardiographic findings in patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Circulation 1978, 58:402–409.

    PubMed  CAS  Google Scholar 

  18. Maron BJ, Wolfson JK, Ciro E, Spirito P: Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 1983, 51:189–194.

    Article  PubMed  CAS  Google Scholar 

  19. Elliott PM, Kaski JC, Prasad K, et al.: Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J 1996, 17:1056–1064.

    PubMed  CAS  Google Scholar 

  20. Frenneaux MP, Porter A, Caforio ALP, et al.: Determinants of exercise capacity in hypertrophic cardiomyopathy. J Am Coll Cardiol 1989, 13:1521–1526.

    Article  PubMed  CAS  Google Scholar 

  21. Chikamori T, Counihan PJ, Doi YL, et al.: Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1992, 19:507–512.

    Article  PubMed  CAS  Google Scholar 

  22. Lele SS, Thomson HL, Seo H, et al.: Exercise capacity in hypertrophic cardiomyopathy: role of stroke volume limitation, heart rate and diastolic filling characteristics. Circulation 1995, 92:2886–2894.

    PubMed  CAS  Google Scholar 

  23. Maron BJ, Epstein SE: Clinical significance and therapeutic implications of left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. Am J Cardiol 1986, 58:1093–1096.

    Article  PubMed  CAS  Google Scholar 

  24. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ: Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991, 84:686–696.

    PubMed  CAS  Google Scholar 

  25. Spirito P, Bellone P, Harris KM, et al.: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778–1785. The magnitude of hypertrophy in HCM is directly related to the risk of sudden death. Young patients with extreme LVH are at high risk even in the absence of symptoms. Most patients with mild LVH are low-risk and can be reassured.

    Article  PubMed  CAS  Google Scholar 

  26. Sugrue DD, McKenna WJ, Dickie S, et al.: Relation between left ventricular gradient and relative stroke volume ejected in early and late systole in hypertrophic cardiomyopathy: assessment with radionuclide cineangiography. Br Heart J 1984, 52:602–609.

    PubMed  CAS  Google Scholar 

  27. Ruzyllo W, Chojnowska L, Demkow M, et al.: Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic cardiomyopathy. Eur Heart J 2000, 21:770–777.

    Article  PubMed  CAS  Google Scholar 

  28. Ziemssen P, Faber L, Schlichting J, et al.: Percutaneous septal ablation in patients with hypertrophic obstructive cardiomyopathy results in improvement of exercise capacity [abstract]. J Am Coll Cardiol 2000, 35:182A.

    Google Scholar 

  29. Redwood DR, Goldstein RE, Hirshfeld J, et al.: Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 1979, 44:215–220.

    Article  PubMed  CAS  Google Scholar 

  30. Nihoyannopoulos P, Karatasakis G, Frenneaux M, et al.: Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol 1992, 19:536–540.

    Article  PubMed  CAS  Google Scholar 

  31. Cuda G, Fananapazir L, Zhu W-S, et al.: Skeletal muscle expression and abnormal function of b-myosin in hypertrophic cardiomyopathy. J Clin Invest 1993, 91:2861–2865.

    Article  PubMed  CAS  Google Scholar 

  32. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ: Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991, 84:686–696.

    PubMed  CAS  Google Scholar 

  33. McKenna WJ, Deanfield J, Faruqui A, et al.: Prognosis in hypertrophic cardiomyopathy: role of age, and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 1981, 47:532–538.

    Article  PubMed  CAS  Google Scholar 

  34. McKenna WJ, Franklin RCG, Nihoyannopoulos P, et al.: Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988, 11:147–153.

    Article  PubMed  CAS  Google Scholar 

  35. Maron BJ, Shen W-K, Link MS, et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365–373. Ventricular tachycardia and ventricular fibrillation are the principal mechanisms of sudden death in HCM. In patients at high risk of sudden death, implantable cardioverter defibrillators are very effective at terminating such arrhythmias and thus have a major role in sudden death prevention.

    Article  PubMed  CAS  Google Scholar 

  36. McKenna WJ, Stewart JT, Nihoyannopoulos P, et al.: Hypertrophic cardiomyopathy without hypertrophy. Br Heart J 1990, 63:287–290.

    PubMed  CAS  Google Scholar 

  37. Maron BJ, Kragel AH, Roberts WC: Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J 1990, 63:308–310.

    PubMed  CAS  Google Scholar 

  38. Anan R, Nakagawa M, Miyata M, et al.: Cardiac involvement in mitochondrial diseases: a study on 17 patients with documented mitochondrial DNA defects. Circulation 1995, 91:955–961.

    PubMed  CAS  Google Scholar 

  39. Pellicia A, Maron BJ, Spataro A, et al.: The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991, 324:295–301.

    Article  Google Scholar 

  40. Maron BJ, Roberts WC, McAllister HA, et al.: Sudden death in young athletes. Circulation 1980, 62:218–229.

    PubMed  CAS  Google Scholar 

  41. Maron BJ, Epstein SE, Roberts WC: Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986, 7:204–214.

    Article  PubMed  CAS  Google Scholar 

  42. Maron BJ, Shirani J, Poliac LC, et al.: Sudden death in young competitive athletes: clinical, demographic and pathological profiles. JAMA 1996, 276:199–204.

    Article  PubMed  CAS  Google Scholar 

  43. Maron BJ, Spirito P, Green KJ, et al.: Non-invasive assessment of diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987, 10:733–742.

    Article  PubMed  CAS  Google Scholar 

  44. Lewis JF, Spirito P, Pellicia A, Maron BJ: Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete’s heart" from hypertrophic cardiomyopathy. Br Heart J 1992, 68:296–300.

    PubMed  CAS  Google Scholar 

  45. Sharma S, Elliott PM, Whyte G, et al.: Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000, 36:864–870. Metabolic exercise testing enables the differentiation between physiologic LVH seen in elite athletes and HCM with mild LVH.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiological Sciences, St. George’s Hospital Medical School, Cranmer Terrace, SW17 0RE, London, England

    Sam Firoozi MRCP, Sanjay Sharma MRCP & William J. McKenna MD, FRCP, FESC, FACC

Authors
  1. Sam Firoozi MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanjay Sharma MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William J. McKenna MD, FRCP, FESC, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Firoozi, S., Sharma, S. & McKenna, W.J. The role of exercise testing in the evaluation of the patient with hypertrophic cardiomyopathy. Curr Cardiol Rep 3, 152–159 (2001). https://doi.org/10.1007/s11886-001-0043-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-001-0043-8

Keywords

Search

Navigation